Hence, a defect of the PD-1/PD-L1 dyad could lead to T1D in a subgroup of patients as the anti-PD-1/PD-L1 therapy triggers T1D in a percentage of individuals and, particularly, on those who carry other T1D susceptibility genes. This evidence concerns the gene CD274 and type 1 diabetes mellitus.